


Tomotherapy means
"slice therapy"

Spiral delivery

Tomotherapy was Designed for IGRT and
IMRT




Tomotherapy

Helical fan-beam IMRT or SRS delivery is fast, effective, and simple

CT is the most important imaging modality for radiotherapy and SRS

Linac on a CT is better than a CT on a linac.

- ✓ ring gantry is more stable than a C-arm gantry
- ✓ CT gantry allows faster rotation
- ✓ no possibility of rotational collisions




PARDISNOOR NILOO

Image guided radiotherapy (IGRT)

Reduction in treatment margins

Allow the use of sharp dose gradients

Interactively adapt to changes within the lesion at the time of treatment



PARDISNOOR IMAGING AND CANCER CENTER


PARDISNOOR NILOO

Tomotherapy



6 MV linac
collimator
85 cm bore
CT detector
768 Xenon cells
beam stopper

Linac

ONCOLOGYMEDICALPHYSICS.COM



Electron Gun
Accelerating Waveguide
Circulator
Waveguide
Modulator
Klystron/Magnetron
Bending Magnet
Treatment Head
Treatment Couch



PARDISNOOR NILOO

Tomotherapy machine components

- ✓ Linear Accelerator
- ✓ MVCT Detector Array
- ✓ Beam stopper
- ✓ Gantry
- ✓ Couch

The diagram illustrates the components of a Tomotherapy machine. It shows a cross-section of the gantry with a linear accelerator at the top, followed by jaws and a multileaf collimator. A detector array is positioned below the collimator, and a beam stop is located at the bottom. Two 85 cm dimensions are indicated: one for the vertical distance from the detector to the jaws, and another for the horizontal width of the detector array.



PARDISNOOR IMAGING AND CANCER CENTER


PARDISNOOR NILOO

Linear Accelerator

This diagram provides a detailed view of the linear accelerator assembly. Labels include: Integrated shielding (top), Linear accelerator (middle), Target (center), Primary Collimator (below target), Moveable Components (Jaws) (bottom left), and Multileaf collimator (MLC) (bottom right).

The mechanical isocenter stability with rotation of the ring gantry¹⁰ is within 0.4 mm




 **Dose Monitor Chambers**

Dose monitoring

the beam passes immediately after traversing through the primary collimator


Dose Monitor Chamber 1 measures the entire photon beam output



Dose Monitor Chamber 2 measures the central portion of the beam



PARDISNOOR IMAGING AND CANCER CENTER

11

 **jaws**




Control field widths


5.0 cm, 2.5 cm, and 1.0 cm

The jaws are made of tungsten alloy

PARDISNOOR IMAGING AND CANCER CENTER


14

 **Multileaf Collimator (MLC)**



MLC: 64 binary, movable, interlaced leaves (tongue and groove design)


Leaf: made of tungsten
ten centimeters thick in the in-beam direction,
2 mm wide (IEC X) on the LINAC side
3 mm wide on the patient side


 Binary MLCs are provided two positions

- Open
- Closed

Open-close time of 20ms

Maximum FOV=40cm






The diagram illustrates the Intensity Modulated Radiation Therapy (IMRT) process. It shows a cross-section of the treatment head with the Multi-Leaf Collimator (MLC) leaves. The top part shows leaves 54, 36, 34, 10, 8, and 6 closed, with a BEV of MLC (Beam's Eye View) showing the resulting intensity profile. The bottom part shows leaves 55, 35, and 33 closed. A vertical arrow indicates 'Patient motion'. Labels include 'Back Y-Jaw' and 'Front Y-Jaw'. The logo 'PARDISNOOR NILOO' is in the top left.

IMRT: treat with optimized leaf specific opening times

Modulation Factor(MF): LOT_{max}/LOT_{mean}

MF: Impacts the gantry's rotation speed




The diagram shows the shielding components of a treatment head. It includes a cross-section of the head showing the primary collimator and the surrounding lead shielding. A text box states: 'Around the primary collimator Protection from scattered photon 12.7 cm of lead'. Below this, two bullet points are listed: '➤ "beam stop"' and '➤ Reduction in vault shielding'. The logo 'PARDISNOOR NILOO' is in the top left. A detailed diagram of the treatment head is shown on the right, with labels for 'Linear Accelerator', 'Beam Stop', 'Detector', 'Beam Stop', 'Multifield Collimator', and 'Beam Stop'. The logo 'PARDISNOOR IMAGING AND CANCER CENTER' is in the center.

Shielding

Around the primary collimator
Protection from scattered photon
12.7 cm of lead


- "beam stop"
- Reduction in vault shielding




Geometry

SAD=85 cm
Bore=85 cm

- Real isocenter (1)
- Virtual isocenter (2)
- Distance 1-2: 70cm




19




Why a “virtual” isocenter?

- No laser in the bore!
 - No way of knowing where the radiation isocenter is, therefore:
- Introduce a virtual isocenter
- Fixed point outside the bore
- Known distance from the real isocenter
- Used as a reference



20




Lasers

Green


- Fixed
- Intersect at virtual isocenter
- Not used clinically
- testing

Red

- Movable
- Overlap green lasers at start up
- Position is specific to each patient's treatment plan
- Serve as a reference point for patient positioning





21




Projections and beamlet

Projection= 1MLC configuration
 Fixed number of projections per rotation: 51
 One projection=7° arc

Beamlets= beam associated with one leaf Max 64 beamlets per projection

22




Two important parameters

Gantry period: 11.8-60 s


$$\text{Pitch} = \frac{d_{\text{couch}} / \text{rotation}}{\text{field width}}$$

↓
Influences:

- Active rotation
- Couch speed



11




Limiting factors

Rotations Per minute:


- MVCT imaging: $360^\circ / 6 \text{ s}$ (10 RPM)
- TomoHelical delivery:
 - Minimum RPM: $360^\circ / 60$ (1rpm)
 - Maximum RPM: $360^\circ / 11.8$ (~5.08 rpm)
- TomoDirect delivery:
 - Minimum RPM: $360^\circ / 60$ (1rpm)
 - Maximum RPM: $360^\circ / 6$ (10 rpm)

Couch Speed: 0.0125-40 mm/s

Max treatable length: 135cm





14


 **TomoDirect**

Discreet Angles
Table moves between irradiations
Pitch defined slightly differently:

The default pitch value is determined by the selected field width




15

 **MVCT Detector Array**

On-board Single slice detector


640 channels
576 are connected to the Data Acquisition System
520 are located in the imaging beam

The detector is installed with a slight tilt ($< 1^\circ$) about the Y axis



26 271 HFS (S)





Multiple reviews on VMAT vs Tomotherapy

Conclusions
 In the treatment of stage IIB-IIIb NSCLC patients, doses, and shorter treatment delivery time with smaller MU. It is stated that the VMAT plan achieved optimal conformal and homogeneous dose distribution in terms of PTV. TOMO plan showed a slight advantage in reducing the sparing of the total normal lung, mainly in V_{20} and V_{30} , but at the cost that more low-dose area spread to the normal lung and more radiation doses to the heart. These findings may be of value in selecting the optimal modality of radiotherapy for the individual patient with LA-NSCLC. Although all three different IMRT plans were clinically acceptable, VMAT seems to be the optimal treatment planning technique in the dosimetric comparison with TOMO and IMRT as to comprehensive evaluation.

CONCLUSION
 HT and VMAT in complex adjuvant breast irradiation allow a good coverage of target volumes with an acceptable acute tolerance. A longer follow-up is needed to assess the impact of low doses to healthy tissues.

Conclusion
 The analysis of the quality parameters for revealed that the tested TPS can produce plan quality for this dose escalation trial. D good results of HT planning for coverage and homogeneity of these plans, also the TPS for calculation of VMAT and IMRT achieved acceptable results for a double simultaneous integrated boost concept for dose escalation in head and neck cancer delivered by IMRT or VMAT. The tested TPS and IMRT-techniques are allowed for the ESCALOX trial.

CONCLUSIONS
 In a dosimetric comparison for SBBC, HT provided the most favorable dose sparing of OARs and can be considered for patients having a higher risk of normal tissue morbidity. However, HT may increase patient discomfort and treatment uncertainty because of its longer BOT. VMAT enabled a shorter BOT with acceptable doses to OARs and a better CI than IMRT and FIF. Therefore, VMAT can

